| 2026-08-07 | Press release | Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update |
| 2026-08-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-16 | Press release | Gyre Therapeutics Appoints Three New Members to its Board of Directors |
| 2026-07-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-15 | 8-K | Form 8-K/A, Item 2.02 results |
| 2026-06-16 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-01 | Deck | Corporate Presentation June 2026 |
| 2026-05-14 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-12 | Press release | Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosi |
| 2026-05-12 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-04 | Press release | Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Co |
| 2026-05-04 | 8-K | Form 8-K, Item 2.01 |
| 2026-04-27 | Proxy | Definitive proxy statement |
| 2026-04-17 | 8-K | Form 8-K/A, Item 1.01 |
| 2026-03-23 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-17 | Press release | Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB- Induced Liver Fibrosis Treatment |
| 2026-03-13 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-12 | Press release | Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-12 | 8-K | Form 8-K, Item 7.01 |
| 2026-03-02 | Press release | Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline |
| 2026-03-02 | Deck | Gyre Therapeutics – Cullgen Acquisition Presentation |
| 2026-03-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-27 | Deck | Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases |
| 2026-01-05 | Press release | Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre- NDA Meeting |
| 2026-01-05 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-07 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-09-10 | 8-K | Form 8-K, Item 8.01 |
| 2025-08-22 | 8-K | Form 8-K, Item 5.02 |
| 2025-08-11 | Press release | Gyre Therapeutics Reports Second Quarter 2025 and Year- to-Date Financial Results and Provides Business and Leadership Update |
| 2025-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-06-06 | 8-K | Form 8-K, Item 5.07 |
| 2025-05-23 | 8-K | Form 8-K, Item 1.01 |